PMID- 22061177
OWN - NLM
STAT- MEDLINE
DCOM- 20120507
LR  - 20151211
IS  - 1600-5449 (Electronic)
IS  - 0065-1427 (Linking)
IP  - 192
DP  - 2011
TI  - Vigabatrin therapy for refractory complex partial seizures: review of major 
      European trials.
PG  - 16-28
LID - 10.1111/j.1600-0404.2011.01597.x [doi]
AB  - Complex partial seizures (CPS) are a form of localization-related seizures 
      associated with serious comorbidities and risks. CPS can be difficult to treat 
      and may remain refractory to treatment with antiepileptic drugs (AEDs). 
      Refractory CPS (rCPS) can be hazardous because of the potential for severe 
      dysfunction and bodily harm, sometimes with fatal consequences. Control of 
      seizure activity is critical to the clinical management of CPS. Vigabatrin is a 
      unique AED approved in both Europe and the United States as adjunctive therapy 
      for adult patients with rCPS who have responded inadequately to several 
      alternative treatments. This review focuses on appropriately controlled studies 
      of vigabatrin conducted in Europe. Several double-blind studies randomized those 
      with rCPS to treatment with vigabatrin vs placebo, and two evaluated durability 
      of response to long-term, open-label vigabatrin. Endpoints included seizure 
      frequency, treatment satisfaction, and adverse events (AEs). Efficacy outcomes 
      demonstrated that vigabatrin add-on therapy significantly reduced the frequency 
      of seizures. Long-term studies indicated durability of response and tolerability 
      of vigabatrin therapy for up to several years. Treatment satisfaction data 
      indicated a preference for vigabatrin vs placebo for both physicians and study 
      participants. Vigabatrin was well-tolerated with generally mild AEs considered 
      common to AEDs. Vision effects were not formally monitored in these studies. In 
      European trials, vigabatrin was efficacious as adjunctive therapy for rCPS.
CI  - (c) 2011 John Wiley & Sons A/S.
FAU - Ben-Menachem, E
AU  - Ben-Menachem E
AD  - Department of Clinical Neuroscience, Sahlgrenska Academy, Goteborg University, 
      Goteborg, Sweden. Elinor.Ben-Menachem@neuro.gu.se
FAU - Sander, J W
AU  - Sander JW
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Denmark
TA  - Acta Neurol Scand Suppl
JT  - Acta neurologica Scandinavica. Supplementum
JID - 0370337
RN  - 0 (Anticonvulsants)
RN  - 0 (GABA Agents)
RN  - GR120KRT6K (Vigabatrin)
SB  - IM
MH  - Adult
MH  - Anticonvulsants/therapeutic use
MH  - Clinical Trials as Topic
MH  - Double-Blind Method
MH  - Epilepsies, Partial/*drug therapy
MH  - GABA Agents/therapeutic use
MH  - Humans
MH  - Vigabatrin/*therapeutic use
EDAT- 2011/11/09 06:00
MHDA- 2012/05/09 06:00
CRDT- 2011/11/09 06:00
PHST- 2011/11/09 06:00 [entrez]
PHST- 2011/11/09 06:00 [pubmed]
PHST- 2012/05/09 06:00 [medline]
AID - 10.1111/j.1600-0404.2011.01597.x [doi]
PST - ppublish
SO  - Acta Neurol Scand Suppl. 2011;(192):16-28. doi: 10.1111/j.1600-0404.2011.01597.x.